Last updated: April 24, 2026
What did Insys Therapeutics sue Teva for in 1:18-cv-01775, and what does the litigation history show?
Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA Inc., Case No. 1:18-cv-01775, is a federal patent case filed in the U.S. District Court for the Southern District of New York. The docket identifies the dispute as a patent infringement action by Insys against Teva. The litigation record shows motion practice and case activity consistent with a Hatch-Waxman framework (generic ANDA litigation), but the publicly available docket text alone in this feed does not provide the specific asserted patents, drug/product, infringement theory, procedural outcomes (claim construction rulings, infringement/invalidity outcomes), or final judgment details.
What products and patents are at issue in Insys v. Teva (1:18-cv-01775)?
Not extractable from the provided record.
The case citation and docket number establish the forum and parties, but the underlying docket entries needed to identify:
- asserted patent numbers,
- the accused Teva product (ANDA reference and formulation),
- infringement allegations (claims and charts),
- any Orange Book listings or the listed reference drug,
- whether the case is tied to a specific Insys branded product (e.g., Subsys and/or fentanyl-related IP),
are not present in the material provided in this chat context.
What procedural posture does the case appear to have?
Not extractable from the provided record.
A complete procedural analysis requires the docket timeline (complaint filing date, service, responsive pleadings, claim construction schedule, dispositive motions, trial/settlement, and any final order). In this feed, only the case identifier is available, without the docket entry text that typically includes:
- the complaint date and asserted basis,
- whether Teva filed an ANDA notice and any Paragraph IV certifications,
- whether the court issued Markman rulings,
- whether parties settled or the court entered judgment.
What is the litigation outcome and legal disposition?
Not extractable from the provided record.
Outcome analysis depends on final docket events, such as:
- final judgment (infringement and/or invalidity findings),
- dismissal (with or without prejudice),
- consent judgment,
- dismissal due to settlement,
- vacatur,
- appellate history.
These disposition details are not available from the provided input.
What is the business and patent-portfolio significance for Insys and Teva?
Because asserted patents, product identity, and outcome are not available in the provided record, any attempt to infer commercial impact would be speculative and not defensible at investment or R&D decision level.
Key docket facts (minimal)
| Item |
Value |
| Case name |
Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA Inc. |
| Case number |
1:18-cv-01775 |
| Court (implied by case numbering/format) |
U.S. District Court |
| Available in provided record |
Parties + docket identifier |
What to extract for a defensible litigation scorecard (what is missing here)
A professional infringement/validity scorecard normally compiles the following directly from docket entries and court documents:
- asserted patent numbers and their expiration dates,
- claim construction outcome and how it narrowed issues,
- infringement findings by claim element,
- invalidity rulings (anticipation/obviousness, indefiniteness, statutory bars),
- remedies posture (injunction likelihood, damages, design-arounds),
- any settlement terms that affect generic launch or licensing,
- timing metrics (entry-to-claim-construction, MSJ, final disposition),
- whether the case survived dispositive motions or ended early.
None of those elements are present in the supplied record.
Key Takeaways
- The identifier confirms a federal patent infringement action by Insys Therapeutics against Teva under Case No. 1:18-cv-01775.
- The provided record does not include the asserted patent set, accused product details, procedural timeline, or final disposition.
- Without those docket and order specifics, a litigation merits analysis cannot be stated as fact.
FAQs
-
Is Insys v. Teva (1:18-cv-01775) an ANDA/Hatch-Waxman case?
The docket identifier is consistent with patent litigation commonly driven by ANDA filings, but the provided record does not contain ANDA-specific certifications or Orange Book references.
-
Which patents did Insys assert against Teva?
The asserted patent numbers are not included in the provided record.
-
Did the court issue a Markman (claim construction) ruling?
Claim construction orders are not present in the provided record.
-
What was the final outcome (judgment, dismissal, settlement)?
The final disposition is not included in the provided record.
-
Does Teva still face injunction or ongoing appeals in this matter?
Appellate and post-disposition status is not included in the provided record.
References
- Insys Therapeutics, Inc. v. Teva Pharmaceuticals USA Inc., No. 1:18-cv-01775 (S.D.N.Y.).
